Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer-Reference-Cited by-同舟云学术

Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer

Published:2014-09-16 Issue:4 Volume:18 Page:691-697
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Kurokawa Yukinori,Matsuura Nariaki,Kimura Yutaka,Adachi Shinichi,Fujita Junya,Imamura Hiroshi,Kobayashi Kenji,Yokoyama Yuhki,Shaker Mohammed Nouri,Takiguchi Shuji,Mori Masaki,Doki Yuichiro

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-014-0430-7.pdf

Reference19 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

2. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.

3. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936–42.

4. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92–8.

5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of low HER2 expression in gastric cancer: a retrospective, single-center analysis;BMC Cancer;2024-09-02

2. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

3. IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer;Journal of Cancer Research and Clinical Oncology;2024-07-25

4. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study;Signal Transduction and Targeted Therapy;2024-07-15

5. Clinicopathologic Features and Prognosis of HER2-Positive Gastric Cancer;International Surgery;2024-07-01